Mineralys Therapeutics Announces Positive Phase 3 Launch-HTN ...

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant...

Mineralys Therapeutics Announces Positive Phase 3 Launch-HTN ...

Mineralys’ Drug Significantly Cut Blood Pressure in Key Study

An experimental drug from Mineralys Therapeutics Inc. significantly lowered blood pressure in patients with treatment-resistant hypertension in a new study, though several stopped taking it because of side effects.

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association (JAMA). The study highlights the efficacy and safety of lorundrostat, a first-in-class aldosterone synthase inhibitor (ASI), in addressing uncontrolled and treatment-resistant hypertension, a condition linked to severe cardiovascular risks. Th…

Scientists discover a big hidden cause of high blood pressure

High blood pressure, also called hypertension, affects over 1.5 billion people around the world. It increases the risk of serious health problems like heart disease and stroke. For years, doctors and researchers have tried to understand what causes high blood pressure so they can find better ways to prevent and treat it. While many factors […] The post Scientists discover a big hidden cause of high blood pressure appeared first on Knowridge Scie…

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring A 167.92% Potential Upside In The Biotech Sector

Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a burgeoning name in the biotechnology industry, is drawing significant attention from investors with a notable potential upside of 167.92%. This clinical-stage biopharmaceutical company, headquartered in Radnor, Pennsylvania, is involved in developing groundbreaking therapies targeting diseases influenced by dysregulated aldosterone. The company’s focus on cardiorenal conditions, such as hypertension…